Ixekizumab

Ixekizumab Uses, Dosage, Side Effects, Food Interaction and all others data.

Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.

Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ixekizumab
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ixekizumab
Availability	Prescription only
Generic	Ixekizumab
Ixekizumab Other Names	Ixekizumab
Related Drugs	Taltz, Humira, Otezla, Cosentyx, Cimzia, prednisone, naproxen, methotrexate, Enbrel, Remicade
Weight	80mg/ml,
Type	Subcutaneous Solution, Subcutaneous
Formula	C₆₄₉₂H₁₀₀₁₂N₁₇₂₈O₂₀₂₈S₄₆
Weight	146158.0 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ixekizumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.

Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ixekizumab is also used to associated treatment for these conditions: Severe Plaque psoriasis, Moderate Plaque psoriasis

How Ixekizumab works

Toxicity

The most common adverse reactions associated with Ixekizumab treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

Food Interaction

No interactions found.

Ixekizumab Drug Interaction

Unknown: aspirin, charcoal, celecoxib, sulfamethoxazole / trimethoprim, ubiquinone, copper gluconate, carvedilol, glucose, diltiazem, glycerin, heparin, sodium iodide, ferrous sulfate, empagliflozin, arginine, levocarnitine, cysteine, furosemide, acetaminophen, cholecalciferol

Ixekizumab Disease Interaction

Moderate: infections, inflammatory bowel disease, tuberculosisMinor: renal/hepatic impairment

Volume of Distribution

The mean (geometric CV%) volume of distribution at steady-state was 7.11 L (29%) in subjects with plaque psoriasis.

Elimination Route

Following a single subcutaneous dose of 160 mg in subjects with plaque psoriasis, ixekizumab reached peak mean (±SD) serum concentrations (Cmax) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose.